Overview

Open-label Extension Study Of RN624

Status:
Completed

Trial end date:
2008-02-11

Target enrollment:

Participant gender:

Summary

Study RN624-CL007 is planned to be an open-label protocol to enroll subjects who have previously participated in Study No. RN624-CL006. In this study, subjects will receive RN624 on an open-label basis.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Tanezumab